文献速递淋巴瘤造血干细胞移植与细胞治疗

高剂量化疗联合自体干细胞移植治疗结节性淋巴细胞为主型霍奇金淋巴瘤:欧洲血液与骨髓移植学会淋巴瘤工作组的一项回顾性研究

High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
PubMed 文献 · Am J Hematol · 2017-11-09

该回顾性注册研究纳入2003至2013年间向EBMT报告的60例复发或难治且对挽救治疗敏感的结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)患者,首次自体干细胞移植后中位随访56个月,5年无进展生存率和总生存率分别为66%和87%,移植时完全缓解与总生存改善相关(对比部分缓解,P=0.049)。

要点

  • 60例复发或难治NLPHL患者接受首次自体干细胞移植,中位随访56个月,5年无进展生存率66%、总生存率87%。
  • 移植时完全缓解者总生存优于部分缓解者(P=0.049),年龄、诊断至移植时间、既往化疗线数及利妥昔单抗使用未显示显著预测价值。
  • 对挽救治疗敏感的复发或难治NLPHL患者,自体干细胞移植可获得良好的疾病控制和长期生存。

核心结论

  • 对挽救治疗敏感的复发或难治NLPHL患者,自体干细胞移植可获得良好的疾病控制和长期生存,且与诊断至移植的时间间隔无关。

研究设计与样本

  • 欧洲血液与骨髓移植学会(EBMT)淋巴瘤工作组的回顾性注册研究,纳入2003至2013年间报告的60例18岁及以上、复发或难治且对挽救治疗敏感的NLPHL患者,接受首次自体干细胞移植,排除转化为弥漫大B细胞淋巴瘤者。

主要发现

  • 患者中位年龄40岁,男性占83%;诊断至移植中位时间21个月(IQR 13-58),既往治疗中位线数2线(范围1-5),63%曾使用利妥昔单抗。
  • 自体干细胞移植时62%患者达完全缓解、38%达部分缓解;72%患者接受BEAM方案作为高剂量治疗。
  • 中位随访56个月(范围3-105),5年无进展生存率为66%,5年总生存率为87%。
  • 单因素分析中,年龄、诊断至移植时间、既往化疗线数及既往利妥昔单抗使用均未发现对任何生存终点有显著预测价值,仅移植时完全缓解(对比部分缓解)与总生存相关(P=0.049)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Whilst autologous stem cell transplantation (auto-SCT) is considered standard of care for relapsed/refractory classical Hodgkin lymphoma, the role of auto-SCT in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto-SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed/refractory NLPHL who underwent first auto-SCT with disease chemosensitive to salvage therapy. NLPHL transformed to diffuse large B cell lymphoma were excluded. Sixty patients (83% male; median age 40 years) met the eligibility criteria. The median time between diagnosis and transplant was 21 months (IQR 13-58), and the median number of prior treatment lines was 2 (range 1-5), including rituximab in 63% of the patients. At auto-SCT, 62% of the patients were in complete remission (CR) and 38% in partial remission. Seventy-two percent of the patients received BEAM as high-dose therapy. With a median follow-up of 56 months (range 3-105), 5-year progression-free and overall survival (OS) were 66% and 87%, respectively. Univariate comparisons considering age, time from diagnosis to transplant, prior chemotherapy lines, and prior rituximab use failed to identify significant predictors for any survival endpoint except for being in CR at the time of auto-SCT (vs PR, P = .049) for OS. Auto-SCT in patients with relapsed/refractory NLPHL who are sensitive to salvage therapy gives excellent disease control and long-term survival independent of the time interval between diagnosis and transplant.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Akhtar S, Montoto S, Boumendil A, et al. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. Am J Hematol. 2017. PMID: 28971503. doi:10.1002/ajh.24927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。